By Colin Kellaher
Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.
Supernus on Tuesday said the FDA green light makes Onapgo the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced forms of the neurodegenerative disorder.
The Rockville, Md., biopharmaceutical company said it plans to make Onapgo available in the second quarter.
Supernus said Onapgo is a wearable infusion device that provides continuous treatment during the waking day for more consistent control of off periods, which can occur in people with Parkinson's disease when there is a return of symptoms in between medication doses.
Shares of Supernus were recently up 5.5% to $39.42.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 04, 2025 10:10 ET (15:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。